01
Metastatic colorectal cancer: RAS and BRAF
KRAS/NRAS testing is needed to identify resistance to specified anti-EGFR antibody approaches. KRAS G12C now has defined combination-treatment indications in eligible CRC populations; BRAF V600E also alters regimen selection.
Assay and specimen: Validated NGS or PCR covering relevant KRAS/NRAS exons and codons and BRAF V600E; report exact variants and allele fractions.
Clinical interpretation: KRAS G12C is not equivalent to every KRAS mutation. Clinical action depends on the particular variant.
02
HR-positive, HER2-negative breast cancer
In advanced or metastatic HR+/HER2− breast cancer, activating PIK3CA mutations can support certain targeted combinations in an indicated endocrine-resistant setting. FDA has approved inavolisib plus palbociclib and fulvestrant for a defined PIK3CA-mutated population.
Assay and specimen: Validated tissue or cfDNA testing covering relevant PIK3CA hotspots and any required companion diagnostic.
Clinical interpretation: Variant identity, sample origin, possible false-negative plasma results, and previous therapy all affect eligibility.
03
Other tumors and limits to extrapolation
BRAF V600E has defined treatment implications in melanoma and selected other malignancies, but other BRAF variants and PIK3CA mutations do not automatically create standard treatment options in all tumors.
Assay and specimen: Determine exact variant and functional class; assess accompanying RAS/MAPK pathway alterations when necessary.
Clinical interpretation: Interpret in context of tumor, stage, treatment line, and available approved treatment.